Skip to content

Assessment of Novel Intraocular Injection Guide

Assessment of Novel Intraocular Injection Guide

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02315170
Enrollment
50
Registered
2014-12-11
Start date
2014-09-30
Completion date
2015-01-31
Last updated
2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Disease

Keywords

diabetic retinopathy, age-related macular edema

Brief summary

To determine if a novel intraocular injection guide (IIG) reduces patient discomfort during and after intravitreal injections.

Detailed description

This study is being conducted to assess the potential for an intraocular injection guide to increase comfort levels both during and after such injections. The hypothesis is that patients will feel increased comfort from a device which eliminates the need for a speculum while still keeping the eyelids apart, allowing a physician to deliver treatment. The results of this study will allow physicians to select the optimal device for patient comfort and well-being during intravitreal injections

Interventions

DEVICEintraocular injection guide

The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection

DEVICEstandard lid speculum

standard wire lid speculum

Sponsors

Maturi, Raj K., M.D., P.C.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects must be receiving bilateral injections of the same dose of vascular endothelial growth factor (VEGF) inhibitor * Injections in both eyes must be given on the same day * Male or female age 18 years or older

Exclusion criteria

-Any condition or reason that precludes the subject's ability to comply with the study -

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue Scale (VAS)one time for about 30 sec or lessThe VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The scale scores range from 0mm (no pain) to 100mm (very severe pain). The patient marks on the line the point that they feel represents their perception of their current state (no pain to very severe pain).

Countries

United States

Participant flow

Recruitment details

all subjects presenting for bilateral injection were offered the chance to participate in this clinical trail

Pre-assignment details

eyes were chosen for the novel guide or standard lid speculum using a randomizing table

Participants by arm

ArmCount
All Participants
Only subjects needing bilateral ocular injections were included in the study. The total number of participants was 50 (100 eyes). Baseline characteristics were identical in both groups. One eye received the treatment with the injection guide while the fellow eye received the treatment with a standard lid speculum.
50
Total50

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
30 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
Sex: Female, Male
Female
35 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 500 / 50
other
Total, other adverse events
0 / 500 / 50
serious
Total, serious adverse events
0 / 500 / 50

Outcome results

Primary

Visual Analogue Scale (VAS)

The VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The scale scores range from 0mm (no pain) to 100mm (very severe pain). The patient marks on the line the point that they feel represents their perception of their current state (no pain to very severe pain).

Time frame: one time for about 30 sec or less

Population: Total number of subjects is 50 - however as the system here is designed for whole body count (not bilateral organs such as eyes), the total number will appear to be double of actual number of subjects.

ArmMeasureValue (MEDIAN)Dispersion
Intraocular Injection GuideVisual Analogue Scale (VAS)14 mm on the VASStandard Deviation 6
Standard Lid SpeculumVisual Analogue Scale (VAS)33 mm on the VASStandard Deviation 7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026